Copyright © 1999 by the European Society of Cardiology.
Cardioprotection by opening of the KATPchannel in unstable angina
Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil
Royal Brompton and Harefield NHS Trust, London, U.K.
accepted October 14, 1998
Abstract
Aims
To assess the anti-ischaemic and anti-arrhythmic effects and overall safety of nicorandil, an ATP sensitive potassium (K+) channel opener, with ‘cardioprotective’ effects, in patients with unstable angina.
Methods
In a multicentre, randomized, double-blind, parallel-group, placebo-controlled study, oral nicorandil 20mg twice daily or a matching placebo was administered for a minimum of 48h to patients admitted with unstable angina. Treatment was standardized to include, where tolerated, oral aspirin, a beta-blocker and diltiazem. Continuous Holter ECG monitoring was performed for 48h to assess the frequency and duration of transient myocardial ischaemia and any tachyarrhythmia, as the predefined end-points of the study. A pain chart recorded the inci-dence and severity of chest pain throughout the study period. Patients with myocardial infarction identified retrospectively from troponin-T analysis were excluded.
Results
Two hundred and forty-five patients were recruited into the study. Forty-three patients were excluded with an index diagnosis of myocardial infarction, two were not randomized and 12 had unsatisfactory tape data. In the remaining 188 patients, six out of 89 patients (6·7%) on nicorandil experienced an arrhythmia, compared with 17 out of 99 patients (17·2%) on placebo (P=0·04). Three nicorandil patients experienced three runs of non-sustained ventricular tachycardia compared to 31 runs in 10 patients on placebo (P=0·087 patients;P<0·0001 runs). Three nicorandil patients had four runs of supraventricular tachycardia, compared to 15 runs in nine patients on placebo (P=0·14 patients;P=0·017 runs). Eleven (12·4%) patients on nicorandil had 37 episodes of transient myocardial ischaemia (mostly silent) compared with 74 episodes in 21 (21·2%) patients on placebo (P=0·12 patients;P=0·0028 episodes). In the overall safety analysis, which included all patients who received at least one dose of study medication, there were no significant differences in the rates of myo-cardial infarction or death between the nicorandil or placebo-treated groups.
Conclusions
Nicorandil, added to aggressive anti-anginal treatment for unstable angina, reduces transient myocardial ischaemia, non-sustained ventricular, and supraventricular arrhythmia compared to placebo. The anti-arrhythmic activity with nicorandil is probably a secondary effect resulting from its anti-ischaemic action and we suggest that this may be related to its effect on the ATP sensitive potassium channel causing pharmacological preconditioning.
Key Words: Unstable angina, nicorandil, ischaemic preconditioning
f1 Correspondence: Dr K. M. Fox, Consultant Cardiologist, Royal Brompton & Harefield NHS Trust, Sydney Street, London SW3 6NP, U.K.
References
- Neuhaus, KL, Coronary thrombosis–defining the goals, improving the outcome
- Braunwald, E, Mark, DB, Jones, RH, Unstable Angina: Diagnosis and management
- Anderson HV, Cannon CP, Stone PH. One-year results of the thrombolysis in myocardial infarction (TIMI) IIIB clinical trial. J Am Coll Cardiol. 1995;26:1643–1650[Abstract]
- Grambow DW, Topol EJ. Effect of maximal medical therapy on refractoriness of unstable angina pectoris. Am J Cardiol. 1992;70:577–581[CrossRef][Web of Science][Medline]
- Purcell H, Patel D, Mulcahy D, Fox KM. Nicorandil. Cardiovascular drug therapy. Philadelphia: WB Saunders; 1996. p. 1638–45
- Akai K, Wang Y, Sato K. Vasodilatory effect of nicorandil on coronary arterial microvessels: Its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 1995;26:541–547[Web of Science][Medline]
- Yellon DM, Baxter GF, Marber MS. Angina reassessed; pain or protector? Lancet. 1996;347:1159–1162[CrossRef][Web of Science][Medline]
- Krumenacker M, Roland EO. Clinical profile of nicorandil: An overview of its haemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol. 1992;20:S93–S102
- Frampton J, Buckley M, Fitton A. Nicorandil: a review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs. 1992;44:625–655[Web of Science][Medline]
- Kato K, Iinuma H, Hirosawa K. Clinical evaluation of intravenous SG-75 in treatment of unstable angina–a multicentre double-blind comparative study with intravenous ISDN. Rinsho Iyaku. 1991;7:2031–2054
- Fukami K, Haze K, Sumiyoshi T. Beneficial effects of intravenous nicorandil in refractory unstable angina. Eur Heart J. 1988;9:64
- Klein HH, Pich S, Lindert-Heimberg S, Schade-Brittinger C, Maisch B, Nebendahl K. Comparative study on the effects of intracoronary nicorandil and nitroglycerin in ischaemic, reperfused porcine hearts. Eur Heart J. 1995;16:603–609
[Abstract/Free Full Text] - Speechly-Dick M, Grover G, Yellon DM. Does ischaemic preconditioning in the human involve protein kinase C and the ATP-dependent K+. Circ Res. 1995;77:1030–1035
[Abstract/Free Full Text] - Billman GE. Role of the ATP sensitive potassium channel in extracellular potassium accumulation and cardiac arrhythmias during myocardial ischaemia. Cardiovasc Res. 1994;28:762–769
[Free Full Text] - Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning the ischaemic myocardium involve cyclo-oxygenase products. Cardiovasc Res. 1990;24:1020–1023[Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
 |
|
 A Burdess and D Newby Harnessing the preconditioning phenomenon: does remote organ ischaemia provide the answer? Heart, October 1, 2006; 92(10): 1367 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G A Large Contemporary management of acute coronary syndrome Postgrad. Med. J., April 1, 2005; 81(954): 217 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
IONA Study Group Impact of nicorandil in angina: subgroup analyses Heart, December 1, 2004; 90(12): 1427 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schalla, C. B. Higgins, M. Chujo, and M. Saeed Effect of Potassium-Channel Opener Therapy on Reperfused Infarction in Hypertrophied Hearts: Demonstration of Preconditioning by Using Functional and Contrast-Enhanced Magnetic Resonance Imaging Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 193 - 202. [Abstract] [PDF]
|
|
|
|
 |
|
 X.-L. Tang, Y.-T. Xuan, Y. Zhu, G. Shirk, and R. Bolli Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1273 - H1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Joyeux-Faure, C. Arnaud, D. Godin-Ribuot, and C. Ribuot Heat stress preconditioning and delayed myocardial protection: what is new? Cardiovasc Res, December 1, 2003; 60(3): 469 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub Anaesthetics and cardiac preconditioning. Part II. Clinical implications Br. J. Anaesth., October 1, 2003; 91(4): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J P Greenwood, I Malik, P Jennings, and R N Stevenson Haemodynamic and electrocardiographic consequences of severe nicorandil toxicity Emerg. Med. J., January 1, 2003; 20(1): 98 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tsuchida, T. Miura, M. Tanno, J. Sakamoto, T. Miki, A. Kuno, T. Matsumoto, Y. Ohnuma, Y. Ichikawa, and K. Shimamoto Infarct size limitation by nicorandil: Roles of mitochondrial KATP channels, sarcolemmal KATP channels, and protein kinase C J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1523 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Loubani and M. Galinanes Long-term administration of nicorandil abolishes ischemic and pharmacologic preconditioning of the human myocardium: Role of mitochondrial adenosine triphosphate-dependent potassium channels J. Thorac. Cardiovasc. Surg., October 1, 2002; 124(4): 750 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E Newby and K. A A Fox Unstable angina: the first 48 hours and later in-hospital management Br. Med. Bull., October 1, 2001; 59(1): 69 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R D Rakhit and M S Marber Nitric oxide: an emerging role in cardioprotection? Heart, October 1, 2001; 86(4): 368 - 372. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Reimann, F. M. Ashcroft, and F. M. Gribble Structural Basis for the Interference Between Nicorandil and Sulfonylurea Action Diabetes, October 1, 2001; 50(10): 2253 - 2259. [Abstract] [Full Text]
|
|
|
|
|
|
The IONA Study Group Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management Heart, June 1, 2001; 85(6): 9e - 9. [Abstract] [Full Text]
|
|
|
|
|
|
British Cardiac Society Guidelines and Medical Pra and Royal College of Physicians Clinical Effectiveness Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation Heart, February 1, 2001; 85(2): 133 - 142. [Full Text]
|
|
|
|
 |
|
 S.K.S. Lairikyengbam, A.G. Davies, and M.H. Anderson Present treatment options for unstable angina and non-Q-wave myocardial infarction QJM, January 1, 2001; 94(1): 5 - 11. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Yellon and A. Dana The Preconditioning Phenomenon : A Tool for the Scientist or a Clinical Reality? Circ. Res., September 29, 2000; 87(7): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF]
|
|
|
|
|
|
D M Yellon and G F Baxter Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality? Heart, April 1, 2000; 83(4): 381 - 387. [Full Text]
|
|
|
|
|
|
T. Sato, N. Sasaki, B. O'Rourke, and E. Marban Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels J. Am. Coll. Cardiol., February 1, 2000; 35(2): 514 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Purcell and K.M. Fox Improving outcome in acute coronary syndromes -- as good as it gets? Eur. Heart J., November 1, 1999; 20(21): 1533 - 1537. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||